Cargando…

PP2A Level in Colorectal Cancer Cells Predicts the Response of p38 Targeted Therapy

Detalles Bibliográficos
Autores principales:	Shang, Chaowei, Huang, Shile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703724/ https://www.ncbi.nlm.nih.gov/pubmed/26844254 http://dx.doi.org/10.1016/j.ebiom.2015.12.013

Ejemplares similares

PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer
por: Zhang, Yanjie, et al.
Publicado: (2015)

Approaching the challenges of MKK3/p38delta MAPK targeting for therapeutic purpose in colorectal cancer
por: Stramucci, Lorenzo, et al.
Publicado: (2019)

A central role for p38 MAPK in the early transcriptional response to stress
por: Whitmarsh, Alan J
Publicado: (2010)

p38 MAPK inhibition reduces diabetes-induced impairment of wound healing
por: Medicherla, Satyanarayana, et al.
Publicado: (2009)

Targeting neuronal MAPK14/p38α activity to modulate autophagy in the Alzheimer disease brain
por: Alam, John, et al.
Publicado: (2016)

The Expanding Role of p38 Mitogen-Activated Protein Kinase in Programmed Host Cell Death
por: Gräb, Jessica, et al.
Publicado: (2019)

Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
por: Munster, Pamela N, et al.
Publicado: (2001)

Moving miRNAs to therapeutic targets in colorectal cancer
por: McGregor, Mark, et al.
Publicado: (2019)

Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation
por: Shen, Tao, et al.
Publicado: (2018)

Iron chelation inhibits mTORC1 signaling involving activation of AMPK and REDD1/Bnip3 pathways
por: Shang, Chaowei, et al.
Publicado: (2020)

Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer
por: Ferrer, Gerardo, et al.
Publicado: (2022)

How to select colorectal cancer patients for personalized therapy
por: Pfeiffer, Per, et al.
Publicado: (2019)

Advances in immunotherapeutic strategies for colorectal cancer commentary on: tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients by Halama et al
por: Deming, Dustin A.
Publicado: (2016)

Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative Serum Level Evaluation and Design of Novel Peptide Inhibitor Targeting the Same
por: Sahu, Vishal, et al.
Publicado: (2019)

TES inhibits colorectal cancer progression through activation of p38
por: Li, Huili, et al.
Publicado: (2016)

Cancer biomarkers and targeted therapies
por: Shen, Zhiyuan
Publicado: (2013)

Ciclopirox inhibits cancer cell proliferation by suppression of Cdc25A
por: Shen, Tao, et al.
Publicado: (2017)

Prediction of Response in Melanoma Therapy by Systemic Inflammatory Response – One Size Fits Not All
por: Richtig, Georg, et al.
Publicado: (2017)

Rsu1 contributes to cell adhesion and spreading in MCF10A cells via effects on P38 map kinase signaling
por: Kim, Yong-Chul, et al.
Publicado: (2014)

p53 and MYC-regulated squalene epoxidase as Achilles heel in colorectal cancer
por: Fischer, Martin
Publicado: (2023)

Maduramicin Inhibits Proliferation and Induces Apoptosis in Myoblast Cells
por: Chen, Xin, et al.
Publicado: (2014)

Polymorphism of the p38β gene in patients with colorectal cancer
por: DIMBERG, JAN, et al.
Publicado: (2014)

Vitamin D as a Potential Therapeutic Target and Prognostic Marker for Colorectal Cancer
por: Bintintan, Vasile V.
Publicado: (2018)

Chronic tooth pulp inflammation induces persistent expression of phosphorylated ERK (pERK) and phosphorylated p38 (pp38) in trigeminal subnucleus caudalis
por: Worsley, M.A., et al.
Publicado: (2014)

Targeting mutant p53 in cancer: the latest insights
por: Di Agostino, Silvia, et al.
Publicado: (2019)

Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
por: Ahronian, Leanne G., et al.
Publicado: (2015)

Pancreatic Cancer: Targeted Therapy Holds the Promise
por: Zhou, Zhijun, et al.
Publicado: (2021)

Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer
por: Chambers, Setsuko K.
Publicado: (2022)

Liposomes for Tumor Targeted Therapy: A Review
por: Wang, Shile, et al.
Publicado: (2023)

Mitotic exit: Determining the PP2A dephosphorylation program
por: Pereira, Gislene, et al.
Publicado: (2016)

Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway
por: Zhou, Hongyu, et al.
Publicado: (2014)

Tuning WNT-β-catenin signaling via BCL9 proteins for targeting colorectal cancer cells
por: Beaulieu, Jean-François
Publicado: (2015)

Evaluation of Biomarkers for HER3-targeted Therapies in Cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Novel mechanism of resistance to targeted therapies in lung cancer
por: Wang, Walter, et al.
Publicado: (2018)

Disulfidptosis: a new target for metabolic cancer therapy
por: Zheng, Peijie, et al.
Publicado: (2023)

DNA Methylation and Chromatin: Role(s) of Methyl-CpG-Binding Protein ZBTB38
por: de Dieuleveult, Maud, et al.
Publicado: (2018)

WRN suppresses p53/PUMA-induced apoptosis in colorectal cancer with microsatellite instability/mismatch repair deficiency
por: Sobol, Robert W.
Publicado: (2023)

The selenoprotein P–LRP5/6–WNT3A complex promotes tumorigenesis in sporadic colorectal cancer
por: Prabhu, K. Sandeep
Publicado: (2023)

Putting together the psoriasis puzzle: an update on developing targeted therapies
por: Johnson-Huang, Leanne M., et al.
Publicado: (2012)

Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?
por: Zhu, Andrew X
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_oo72snjtigostrrdaohji0j3u3